Funded Startups in Marina Del Rey
Disclosed funding in Marina Del Rey is dominated by a single outlier: Whatnot’s $225M round on 2025-10-30, which dwarfs the next-largest disclosed amount (…
Disclosed funding in Marina Del Rey is dominated by a single outlier: Whatnot’s $225M round on 2025-10-30, which dwarfs the next-largest disclosed amount ($52M from LeaseLock on 2021-02-03). The list also shows a tight concentration of large commercial raises in the 2021 window, with LeaseLock ($52M, 2021-02-03) and Aspiration ($50M, 2021-01-28) followed by Poparazzi’s $20M (2021-05-27) and $15M (2022-06-01). Sector and stage signals are mixed: “Series Unknown” appears repeatedly across entries with both healthcare (e.g., ViyaMD, 2026-07-06) and AI (e.g., OSEM, undisclosed on 2025-08-14), while disclosed amounts range from Hope For Stomach Cancer’s $10K on 2024-09-23 up to $225M. Temporally, rounds span from 2020-07-01 (Riders Share, $2M) through 2026-07-06 (ViyaMD, $5M), with the most recent cluster arriving in 2025–2026.
Most recent rounds
22 shownRelated listings
Frequently asked
Which disclosed round is the clear outlier in Marina Del Rey, and how far above the rest is it?
Whatnot’s $225M (2025-10-30) is the only disclosed amount in the $200M+ range; the next-largest disclosed round is LeaseLock’s $52M (2021-02-03), with Aspiration next at $50M (2021-01-28).
Do the largest financings cluster in a specific time window?
Yes. The 2021–2022 period concentrates multiple top-tier disclosures: Aspiration ($50M, 2021-01-28), LeaseLock ($52M, 2021-02-03), Poparazzi ($20M, 2021-05-27), then later Quadrata ($8M, 2022-07-12) and Recess ($5M, 2022-11-10).
Are there sector over-representations (3+ entries) among these Marina Del Rey companies?
Healthcare appears in multiple entries (e.g., ViyaMD with a 2026-07-06 Seed at $5M; Armata Pharmaceuticals in 2026-06-23 with $3M; Hope For Stomach Cancer at $10K on 2024-09-23). AI also repeats (LeaseLock on 2021-02-03 for $52M; Mobalytics on 2020-07-22 for $11M; OSEM with undisclosed funding on 2025-08-14).
How often is “Series Unknown” used, and what does that imply about comparability across rounds?
“Series Unknown” shows up across several entries (for example, Armata Pharmaceuticals on 2026-06-23 with $3M and Alvee on 2026-05-04 with $3M; OSEM on 2025-08-14 is undisclosed). That mix means some of the largest outcomes can’t be easily benchmarked by stage label in this slice (versus labeled rounds like Whatnot’s Series F on 2025-10-30).
Which entries are the most recent 90 days by round date, and do they include large disclosed raises?
In the most recent window, ViyaMD (2026-07-06, $5M) and Armata Pharmaceuticals (2026-06-23, $3M) are among the latest, with Spring Labs (2026-05-05, $5M) and Alvee (2026-05-04, $3M) also inside that range. The only very large disclosed raise in the broader recent period is Whatnot’s $225M on 2025-10-30; the latest 90 days here don’t include another comparable disclosed size.
Are there unusually small disclosed rounds that contrast with the rest of the list?
Yes. Hope For Stomach Cancer is a pronounced low-end disclosed outlier at $10K on 2024-09-23, sitting far below the next-small disclosed figures such as Open Earth Foundation’s $350K (2023-12-20) and Seed rounds like Seatopia’s $2M (2024-08-27).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.